Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGFβ1 expression

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 295, Issue 3, 2008, Pages

  Malizia, Andrea P ^a   Keating, Dominic T ^a   Smith, Sinead M ^b   Walls, Dermot ^b   Doran, Peter P ^a   Egan, Jim J ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Epithelial injury; Ganciclovir; Idiopathic pulmonary fibrosis; Transforming growth factor 1

Indexed keywords

CASPASE 3; CASPASE 7; GANCICLOVIR; GENE PRODUCT; RNA; TRANSFORMING GROWTH FACTOR BETA1; ANTIVIRUS AGENT; PRIMER DNA; SMALL INTERFERING RNA;

ARTICLE; CELL DAMAGE; CELL PROLIFERATION; CONTROLLED STUDY; EARLY RESPONSE GENE; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG ALVEOLUS EPITHELIUM; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS EXPRESSION; VIRUS INDUCTION; VIRUS INFECTION; APOPTOSIS; CELL CULTURE; CELL LINE; DRUG EFFECT; EPITHELIUM CELL; GENETICS; IMMEDIATE EARLY GENE; INJURY; LUNG ALVEOLUS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PATHOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; APOPTOSIS; BASE SEQUENCE; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; DNA PRIMERS; EPITHELIAL CELLS; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; GENES, IMMEDIATE-EARLY; HERPESVIRUS 4, HUMAN; HUMANS; PULMONARY ALVEOLI; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 52649086420     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00376.2007     Document Type: Article

References (41)

1. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003.
2. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21: 2933-2942, 2005.
3. Cayrol C, Flemington EK. The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J 15: 2748-2759, 1996.
4. Cayrol C, Flemington EK. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1. J Virol 7: 4206-4212, 1995.
5. Chang Y, Chang SS, Lee HH, Doong SL, Takada K, Tsai CH. Inhibition of the Epstein-Barr virus lytic cycle by Zta-targeted RNA interference. J Gen Virol 85: 1371-1379, 2004.
6. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
7. Cox MA, Leahy J, Hardwick JM. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J Virol 64: 313-321, 1990.
8. Datta AK, Feighny RJ, Pagano JS. Induction of Epstein-Barr virus-associated DNA polymerase by 12-O-tetradecanoylphorbol-13-acetate. Purification and characterization. J Biol Chem 255: 5120-5125, 1980.
9. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3, 2003.
10. Egan JJ, Stewart JP, Hasleton PS, Arrand JR, Carroll KB, Woodcock AA. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 50: 1234-1239, 1995.
11. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998.
12. Fahmi H, Cochet C, Hmama Z, Opolon P, Joab I. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J Virol 74: 5810-5818, 2000.
13. Gentry M, Taormina J, Pyles RB, Yeager L, Kirtley M, Popov VL, Klimpel G, Eaves-Pyles T. Role of primary human alveolar epithelial cells in host defense against Francisella tularensis infection. Infect Immun 75: 3969-3978, 2007.
14. Gruffat H, Sergeant A. Characterization of the DNA-binding site repertoire for the Epstein-Barr virus transcription factor R. Nucleic Acids Res 22: 1172-1178, 1994.
15. Hardwick JM, Tse L, Applegren N, Nicholas J, Veliuona MA. The Epstein-Barr virus R transactivator Rta contains a complex, potent activation domain with properties different from those of VP16. J Virol 66: 5500-5508, 1992.
16. Hergenhahn M, Soto U, Weninger A, Polack A, Hsu CH, Cheng AL, Rosl F. The chemopreventive compound Curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells. Mol Carcinog 3: 137-145, 2002.
17. Holley-Guthrie EA, Quinlivan EB, Mar EC, Kenney S. The Epstein-Barr virus EBV. BMRF1 promoter for early antigen EA-D is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol 64: 3753-3759, 1990.
18. 18a. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 4: P4, 2003.
19. Imai S, Nishikawa J, Takada K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 72: 4371-4378, 1998.
20. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 1: 65-74, 2002.
21. Jia Q, Sun R. Inhibition of gammaherpesvirus replication by RNA interference. J Virol 5: 3301-3306, 2003.
22. Keating DT, Sadlier DM, Patricelli A, Smith SM, Walls D, Egan JJ, Doran PP. Microarray identifies ADAM family members as key responders to TGF-beta1 in alveolar epithelial cells. Respir Res 7: 114, 2006.
23. Kieran NE, Doran PP, Connolly SB, Greenan MC, Higgins DF, Leonard M, Godson C, Taylor CT, Henger A, Kretzler M, Burne MJ, Rabb H, Brady HR. Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int 64: 480-492, 2003.
24. Lok SS, Haider Y, Howel D, Stewart JP, Hasleton PS, Egan JJ. Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice. Eur Respir J 20: 1228-1232, 2002.
25. Lung ML, Lam WK, So SY, Lam WP, Chan KH, Ng MH. Evidence that respiratory tract is major reservoir for Epstein-Barr virus. Lancet 1: 889-892, 1985.
26. Mason RJ. Biology of alveolar type II cells. Respirology 11: S12-S15, 2006.
27. Mauser A, Holley-Guthrie E, Simpson D, Kaufmann W, Kenney S. The Epstein-Barr virus immediate-early protein BZLF1 induces both a G2 and a mitotic block. J Virol 76: 10030-10037, 2002.
28. Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 45: 2082-2091, 2001.
29. Mora AL, Woods CR, Garcia A, Xu J, Rojas M, Speck SH, Roman J, Brigham KL, Stecenko AA. Lung infection with γ-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. Am J Physiol Lung Cell Mol Physiol 289: L711-L721, 2005.
30. Mora AL, Torres-González E, Rojas M, Xu J, Ritzenthaler J, Speck SH, Roman J, Brigham K, Stecenko A. Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice. Am J Respir Crit Care Med 11: 1139-1150, 2007.
31. Pfeffer U, Ferrari N, Dell'Eva R, Indraccolo S, Morini M, Noonan DM, Albini A. Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: microarray gene expression analyses. Mutat Res 591: 198-211, 2005.
32. Ragoczy T, Heston L, Miller G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol 72: 7978-7984, 1998.
33. Sato K, Tomioka H, Shimizu T, Gonda T, Ota F, Sano C. Type II alveolar cells play roles in macrophage-mediated host innate resistance to pulmonary mycobacterial infections by producing proinflammatory cytokines. J Infect Dis 185: 1139-1147, 2002.
34. Schug J, Overton GC. Technical Report CBIL-TR-1997-1001-v0.0 (On-line). Computational Biology and Informatics Laboratory School of Medicine, Univ. of Pennsylvania, Philadelphia, PA, 1997. http://www.cbil.upenn.edu/cgi-bin/tess/tess.
35. Schuster N, Krieglstein K. Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res 1: 1-14, 2002.
36. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134: 136-151, 2001.
37. Stewart JP, Egan JJ, Ross AJ, Kelly BG, Lok SS, Hasleton PS, Woodcock AA. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 159: 1336-1341, 1999.
38. Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, Brigham KL, Oates JA Jr, Loyd JE, Stecenko AA. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 41: 2633-2640, 2003.
39. Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 55: 958-961, 2000.
40. Ulich TR, Yi ES, Longmuir K, Yin S, Biltz R, Morris CF, Housley RM, Pierce GF. Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 93: 1298-1306, 1994.
41. Zalani S, Holley-Guthrie E, Kenney S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci USA 93: 9194-9199, 1996.